Democrats push for stem cell vote in US Senate
By Reuters,
Reuters
| 05. 04. 2006
WASHINGTON (Reuters) - Senate Democrats sought on Thursday to jump-start a long-awaited debate on legislation to allow federal funding of embryonic stem cell research by considering it while it debates other health measures this month.
The Democrats sent a letter to Majority Leader Bill Frist asking him to add stem cells to what Republicans have dubbed "health week." Frist wants the Senate to consider other health legislation, possibly next week, on medical malpractice and small business insurance.
Despite a veto threat by President George W. Bush, the U.S. House of Representatives passed a bipartisan bill last year backing research on excess embryos that would otherwise be discarded by fertility clinics.
The Senate has not taken up the bill, Frist, a Tennessee Republican, broke with other conservatives to embrace it in a surprise move last summer.
"Further delay will mean more lost opportunities for new cures and new treatments," leading Democrats said in a letter to Frist to be made public on Thursday.
The letter to Frist from Senate Democratic leader Harry Reid of Nevada, stem cell bill co-sponsor Tom Harkin...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
